Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US

被引：1
|
作者：
Petersen, Tonny Studsgaard [1 ,2 ]
Karstoft, Kristian [1 ,2 ]
Sorup, Freja Karuna Hemmingsen [1 ,2 ]
Lund, Marie [1 ,2 ,3 ]
Cramer, Allan [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Clin Pharmacol, Bispebjerg Bakke 23,2400 Kbh NV, DK-2400 Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark
来源：
JAMA ONCOLOGY | 2025年 / 11卷 / 01期
关键词：
D O I：
10.1001/jamaoncol.2024.5145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [1] Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
    Shahzad, Mahnum
    Naci, Huseyin
    Esselen, Katharine M.
    Dottino, Joseph A.
    Wagner, Anita K.
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2024, 17 (01)
  • [2] Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval
    Shahzad, Mahnum
    Naci, Huseyin
    Wagner, Anita K.
    JAMA INTERNAL MEDICINE, 2021, 181 (12) : 1673 - 1675
  • [3] Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US
    Jazowski, Shelley A.
    Vaidya, Avi U.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    Sachs, Rachel E.
    JAMA INTERNAL MEDICINE, 2023, 183 (07) : 737 - 739
  • [4] Approval probabilities and regulatory review patterns for anticancer drugs in the European Union
    Hartmann, Markus
    Mayer-Nicolai, Christine
    Pfaff, Otmar
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 87 (02) : 112 - 121
  • [5] Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
    Parikh, Ravi B. B.
    Hubbard, Rebecca A. A.
    Wang, Erkuan
    Royce, Trevor J. J.
    Cohen, Aaron B. B.
    Clark, Amy S. S.
    Mamtani, Ronac
    JAMA ONCOLOGY, 2023, 9 (04) : 567 - 569
  • [6] Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
    Ho, Cheryl
    Lim, Howard J.
    Regier, Dean A.
    JAMA NETWORK OPEN, 2021, 4 (08)
  • [7] Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States
    Iglesias-Lopez, Carolina
    Obach, Merce
    Vallano, Antonio
    Agusti, Antonia
    CYTOTHERAPY, 2021, 23 (03) : 261 - 274
  • [8] Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union
    Radhakrishna, Swetha
    Dahiya, Meghana
    Pipalava, Parag
    Jose, Vinu
    PHARMACEUTICAL MEDICINE, 2021, 35 (02) : 93 - 112
  • [9] Regulatory Approval Scenario of Biosimilars in Pediatric Patients in the United States and European Union
    Swetha Radhakrishna
    Meghana Dahiya
    Parag Pipalava
    Vinu Jose
    Pharmaceutical Medicine, 2021, 35 : 93 - 112
  • [10] Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan
    Akira Ito
    Mamoru Narukawa
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 136 - 142
12345